4D Molecular Therapeutics, Inc. (FDMT)
NASDAQ: FDMT · Real-Time Price · USD
2.990
-0.240 (-7.43%)
Apr 1, 2025, 4:00 PM EDT - Market closed

4D Molecular Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019 - 2017
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019 - 2017
Net Income
-160.87-100.84-107.49-71.32-56.69
Upgrade
Depreciation & Amortization
6.715.753.883.021.44
Upgrade
Loss (Gain) From Sale of Investments
-7.18-1.241.060.72-
Upgrade
Stock-Based Compensation
26.1819.7517.2113.895.03
Upgrade
Other Operating Activities
0.040.16-00.090.02
Upgrade
Change in Accounts Receivable
--0.051.44-0.51
Upgrade
Change in Accounts Payable
0.870.9-1.642.290.04
Upgrade
Change in Unearned Revenue
0.07-0.72-3.13-14.720.35
Upgrade
Change in Other Net Operating Assets
-0.40.453.39-4.54-0.59
Upgrade
Operating Cash Flow
-134.59-75.79-86.69-69.13-50.91
Upgrade
Capital Expenditures
-3.79-2.77-11.54-9.11-1
Upgrade
Investment in Securities
-298.65118.49-5.51-163.57-
Upgrade
Investing Cash Flow
-302.44115.72-17.05-172.68-1
Upgrade
Issuance of Common Stock
337.25156.833.55118.09206.52
Upgrade
Other Financing Activities
---0.47--3.14
Upgrade
Financing Cash Flow
337.25156.833.09118.09278.98
Upgrade
Net Cash Flow
-99.77196.76-100.65-123.73227.07
Upgrade
Free Cash Flow
-138.37-78.56-98.22-78.24-51.91
Upgrade
Free Cash Flow Margin
-373975.68%-379.11%-3139.05%-433.77%-381.35%
Upgrade
Free Cash Flow Per Share
-2.56-2.01-3.04-2.82-8.07
Upgrade
Levered Free Cash Flow
-82.29-46.48-59.7-41-29.23
Upgrade
Unlevered Free Cash Flow
-82.29-46.48-59.7-41-29.23
Upgrade
Change in Net Working Capital
-6.01-1.330.494.21-0.72
Upgrade
Updated Feb 28, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q